Morepen Labs Proposes Dividend After 23 Years; Revenue Rises 7.4% in FY25

Morepen Laboratories Ltd has proposed a dividend of ₹0.20 per share for FY25, marking its first such move in 23 years. This milestone is subject to shareholder approval at the upcoming Annual General Meeting.

Sushil Suri, Chairman & Managing Director of Morepen Laboratories Ltd, said, “This moment is symbolic – it’s not just about distributing profits; it’s about rewarding trust. We always believe in the “Joy of Growing Together”. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it’s time we give back.”

Financial Performance in FY25

The dividend declaration follows the financial performance report. Gross revenue for FY25 reached ₹1,830 crore, reflecting a 7.4% YoY increase from ₹1,704 crore in FY24. EBITDA grew by 11.5% to ₹192 crore, while Profit After Tax rose to ₹118 crore. Earnings Per Share (EPS) also improved, rising 17% YoY to ₹2.20.

API and Medical Devices Drive Growth

Morepen’s API (Active Pharmaceutical Ingredient) business remained a major revenue contributor, generating ₹989 crore. The Medical Devices segment also saw notable growth, reaching ₹496 crore, a 12% rise over the previous year. Notably, 72% of API revenues came from exports to over 80 countries, underscoring the company’s strong international presence.

Continued Focus on Innovation and Expansion

The company is investing in product development, expanding manufacturing capacity, and securing global regulatory approvals to support long-term growth.

Morepen Laboratories Share Price Performance

On May 13, 2025, Morepen Laboratories share price (NSE: MOREPENLAB) opened at ₹59.26, slightly down from its previous close of ₹60.36. At 10:26 AM, the share price of Morepen Laboratories was trading at ₹59.70, down by 1.09% on the NSE.

Also Read: Morepen Laboratories Launches Empamore For Affordable Diabetes Treatment!

Conclusion

Morepen’s return to dividend payouts reflects its improved financial position and strategic focus. The company remains committed to strengthening its global footprint and product offerings.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.